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A B S T R A C T
Objectives: This study aimed to compare differences in mortality risk factors between admission and
follow-up incorporated models.
Methods: A retrospective cohort study of 524 patients with confirmed COVID-19 infection admitted to a
tertiary medical center in São Paulo, Brazil from 13 March to 30 April 2020. Data were collected on
admission, and the third, eighth and fourteenth days of hospitalization. The hazard ratio (HR) was
calculated and 28-day in-hospital mortality risk factors were compared between admission and follow-
up models using a time-dependent Cox regression model.
Results: Of 524 patients, 50.4% needed mechanical ventilation. The 28-day mortality rate was 32.8%.
Compared with follow-up, admission models under-estimated the mortality HR for peripheral oxygen
saturation <92% (1.21 versus 2.09), heart rate >100 bpm (1.19 versus 2.04), respiratory rate >24/min (1.01
versus 1.82) and mechanical ventilation (1.92 versus 12.93). Low oxygen saturation, higher oxygen
support and more biomarkers–including lactate dehydrogenase, C-reactive protein, neutrophil-
lymphocyte ratio, and urea remained associated with mortality after adjustment for clinical factors
at follow-up compared with only urea and oxygen support at admission.
Conclusions: The inclusion of follow-up measurements changed mortality hazards of clinical signs and
biomarkers. Low oxygen saturation, higher oxygen support, lactate dehydrogenase, C-reactive protein,
neutrophil-lymphocyte ratio, and urea could help with prognosis of patients during follow-up.
© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Introduction
The SARS-CoV-2 virus has infected more than 100 million and
killed nearly 2.5 million people worldwide over the past few
months (JHU, 2020). Although most patients are asymptomatic or
have mild symptoms, 10% of them require hospitalization and 5%
advanced medical support (Wu and McGoogan, 2020). Early
identification of severe cases that will demand longer hospital-
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reas.
Clinical risk factors associated with disease progression and
eath (Center for Diseases Control, 2020; Giannouchos et al., 2020;
ian et al., 2020; Wang et al., 2020) identified in observational
tudies include older age, hypertension, diabetes, cardiovascular
isease, pulmonary disease, chronic renal disease, and cancer.
lthough there is conflicting evidence about the relative risk of
ome (e.g., hypertension (Tadic et al., 2020)), a lack of morbidities
eems to be protective. Male gender (Boulle et al., 2020;
alaiodimos et al., 2020) and non-white ethnicity (Sze et al.,
020) have also been associated with mortality in some studies.
Among patients hospitalized with COVID-19, several biomark-
rs have been associated with poor outcomes (Malik et al., 2020;
od et al., 2020). Non-survivors have been shown to have lower
ymphocyte counts and higher levels of D-dimer, C-reactive protein
CRP), lactate dehydrogenase (LDH), and interleukin-6 on admis-
ion compared with discharged patients. However, few studies
ave taken into consideration subsequent (from admission)
iomarker levels (Berzuini et al., 2020; Ye et al., 2020) and
onsequently there is limited validity of their prognostic ability for
ollow-up reassessments during a hospital stay. In addition, few
iomarkers remain associated after adjustment for clinical factors.
Although >20 million people have been infected by COVID-19 in
atin America (JHU, 2020), clinical information on patients’
haracteristics and outcomes in this region are lacking. This study
imed to: (i) describe the profile of patients admitted with COVID-
9 infection to the largest tertiary publicly-funded hospital in
razil during the first two months of the coronavirus pandemic;
nd (ii) compare the predictive performance and measures of
ssociation between a model with only admission variables and
nother with the inclusion of repeated measurements throughout
ospitalization.
ethods
tudy design and population
A retrospective cohort study was carried out on consecutive
atients diagnosed with SARS-CoV-2 infection admitted to
ospital das Clínicas, a University of São Paulo affiliated institution,
rom 13 March to 30 April 2020. SARS-CoV-2 infection was
onfirmed after a positive real-time quantitative reverse tran-
cription polymerase chain reaction (RT-qPCR) test on a nasopha-
yngeal or tracheal swab test. During the aforementioned period,
ospital das Clínicas was included in the regional COVID-19 plan to
eceive only highly suspected or confirmed cases in need of
dvanced care support (e.g. renal replacement therapy) unavail-
ble at the origin. An assessment algorithm that included the
equential Organ Failure Assessment (SOFA) and expected long-
erm survival was used for prioritization of beds. The institutional
rotocol recommended antibiotics (if pneumonia) and prophylac-
ic anticoagulation; hydroxychloroquine and corticosteroids were
ptional. Patients with 24 h of hospitalization, admission
iagnoses other than COVID-19, and aged <18 years were excluded.
nly the first admission was considered in cases in which more
han one was observed. The final cohort included 524 admissions.
he project was approved by the National Ethics Committee under
esearch protocol no. 31090720.0.0000.0068.
onset, vital signs, oxygen support, and laboratory exams. Oxygen
support was categorized into four groups reflecting different
levels of oxygen dependency: room air, nasal catheter, interme-
diate oxygen support (Venturi mask, non-rebreather masks,
BiPAP and high-flow nasal cannula), and mechanical ventilation.
Previously known comorbidities and regular medications were
manually retrieved throughout hospitalization. A diagnosis of
obesity was retrieved from medical notes because data on weight
and height were mostly missing. To analyze the effects of clinical
follow-up on mortality, vital signs, laboratory exams and current
oxygen support on the third, eighth and fourteenth days of
hospitalization were also collected; these days were chosen to
reflect both a short and long period of follow-up from admission.
Vital signs collection was standardized to the first measurement
after 06:00, except for temperature, which was the highest
measure of the day.
Medication
Daily medical prescriptions were collected in the first 14 days
following admission and re-classified into major groups when
more than one single agent was prescribed (e.g. intravenous
corticosteroids). To examine the rates of unfractionated heparin
(UFH) and low-molecular-weight heparin (LMWH) dosage pre-
scriptions, the prescribed dosage was divided into three groups
during data collection: prophylactic (subcutaneous UFC  15.000
IU/day or subcutaneous LMWH  40 mg/day); optimized
(subcutaneous UFC > 15.000 or subcutaneous LMWH > 40 mg/
day and <2 mg/kg/day) and anticoagulation (intravenous UFC or
subcutaneous LMWH  2 mg/kg/day).
Outcomes
The primary outcome was 28-day mortality. Patients still
hospitalized at 28 days were considered alive. Secondary outcomes
included overall mortality, thrombotic complications (stroke,
myocardial infarction, deep vein thrombosis, and pulmonary
thromboembolism) and need for renal replacement therapy.
Statistical analysis
Categorical variables were described with the absolute number
and respective percentage, and continuous variables with the
median, mean, standard deviation (SD) or interquartile range
(IQR), according to variable distribution. Kaplan-Meier survival
curves with the inverse probability weights failure function were
used to describe the occurrence of deaths on the 28th day of
hospitalization (dependent variable). The covariates to be tested
(independent variables) were selected based on prior knowledge
and vital signs were categorized (e.g. temperature 37.8 C) to
account for possible non-linear associations. Ethnicity was
categorized as white and non-white, due to the small number of
sub-groups within the non-white category. To analyze the effects
of follow-up variables on mortality, two models were created: one
solely based on admission variables, and another with the
inclusion of repeated measurements of clinical vital signs and
laboratory exams during hospitalization (days 3, 8 and 14). To
model the latter, a time-dependent-covariates Cox model was used
(Therneau et al., 2020), in which a new time interval was created
after a new measurement was added, and an event (death) couldlinical variables
All clinical information on demographics, medical morbidities
nd clinical follow-up were retrieved from electronic health
ecords through a standardized form. The following variables
ere collected from admission: symptoms, time from symptom72happen at every end of an interval. Following this approach, a given
subject could have multiple observations but would not have
overlapping intervals, and consequently the model was spared
from within-subject correlation. Medication prescription and
outcomes were not measured because, for most medications
studied, there are already ongoing clinical trials (state-of-art for4
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treatment.
Univariable Cox regressions were run for each covariate
against the outcome for both admission and time-dependent
variables. All covariates with a p-value 0.20 were included in a
multivariable model for confounding adjustment following a
hierarchical framework approach from distal (age, ethinicity and
sex) to proximal (vital signs and laboratoray exams) determi-
nants. If after the inclusion the variable maintained p  0.20, it
was kept in the model; otherwise, it was discarded from
subsequent models. Exceptions included age, sex and ethnicity
that were included in all models, and vital signs that were tested
in the multivariable model regardless of the univariable statistical
value. A baseline model with age, sex, ethnicity, and comorbid-
ities was first created, and then two subsequent models
(admission and follow-up) were built upon it. The final models
are shown in the article and all intermediate ones are in the
supplementary material. Cox proportional hazard assumption
was evaluated using Schoenfeld residuals and model performance
with Harrell’s c-statistic.
Few missing values were found (<5%) for most clinical
variables except previous medication and laboratory exams
(Supplementary Tables 1 and 2). A complete-case analysis was
used in the article but a sensitivity analysis with imputation was
provided in the supplementary material. Multiple imputations
with chained equations (MICE) were performed and Rubin’s rules
were used (Rubin, 2004) to combine results over 10 imputed
datasets. Because of the repeated measurements, imputation
followed a multi-level procedure with the participant identifica-
tion as a cluster for mixed effects. Discrepancies between
complete-case and imputation analysis were reported through-
out the paper. The alpha was set at 5% (two-tailed). Statistical
analysis was performed in R version 3.6.2 (R Core Team 2013)
using the MICE (Buuren and Groothuis-Oudshoom, 2010) and
survival package (Therneau, 2020).
Results
Patients characteristics and outcomes
Table 1 describes patients’ characteristics at admission and
their hospitalization outcomes. Of 524 patients, the mean age was
58.7 years (SD 16.4) and most were male (57.44%) with white skin
color (68.46%); 131 (25.79%) had smoking exposure. The most
common comorbidity was hypertension (59.25%) followed by
diabetes (38.58%) and obesity (24.8%). Over one-third of the
patients were taking angiotensin-converting enzyme inhibitors
(ACEi) or angiotensin receptor blockers (ARB) before admission.
Many patients had active cancer (13.78%) or previous solid organ
transplant (3.94%). The median time from symptom onset to
admission was 7 days. Patients had high respiratory rates and low
peripheral oxygen saturation in addition to low lymphocyte counts
and high levels of D-dimer, CRP and LDH on admission.
Over 24% of the patients were admitted already on mechanical
ventilation, and nearly half of them were intubated during
hospitalization. The median (IQR) duration of mechanical ventila-
tion was 10 (518) days. Nearly 60% (333) were transferred to
intensive care units (ICU) and 50% of them died. Thrombotic events
were observed in 9.7% of the patients and common complications
included deep vein thrombosis (4.21%) and pulmonary thrombo-
Table 1
Patients characteristics at admission and outcomes.
N = 524
















Active cancer 70 (13.78%)
Congestive heart failure 58 (11.42%)
Chronic kidney disease 52 (10.24%)
Atherosclerotic disease 52 (10.24%)
Asthma 22 (4.33%)
COPD 20 (3.94%)
Previous transplant 20 (3.94%)
Dyalisis 13 (2.56%)
Connective tissue disease 9 (1.77%)
Cirrhosis 5 (0.98%)
Medications
ACE or ARB 137 (37.23%)
Days of symptoms, Median (IQR) 7 (49)
Vital signs
Systolic pressure, Mean (SD) 125.22 (21.8)
Diastolic pressure, Mean (SD) 75.94 (13.1)
Respiratory frequency, Mean (SD) 25.38 (7.06)
Oxygen saturation, Mean (SD) 92.56 (6.42)
Heart rate, Mean (SD) 90.53 (16.68)
Temperature, Mean (SD) 36.49 (0.99)
Oxygen supplementation
Room air 143 (27.71%)
Nasal catheter 173 (33.53%)
Intermediate oxygen support 75 (14.53%)
Mechanical ventilation 125 (24.22%)
Need for vasoactive drugs 82 (15.95%)
Laboratory exams
Creatinine (mg/dL), Median (IQR) 0.97 (0.741.6)
Urea (mg/dL), Median (IQR) 39 (2664)
Leucocytes (*1000/mm3), Median (IQR) 7.56 (5.4110.59)
Lymphocytes (*1000/mm3), Median (IQR) 0.9 (0.61.3)
Platelets (*1000/mm3), Median (IQR) 196 (151261)
D-dimer (ng/dL), Median (IQR) 1345 (692.253,181.75)
C-reactive protein (mg/L), Median (IQR) 148.25 (77.83249.5)
Lactic dehydrogenase (U/L), Median (IQR) 403.5 (309546)
Hospitalization Days, Median (IQR) 12 (621)
Mortality
In-hospital mortality 192 (36.92%)
28-day in-hospital mortality 172 (32.82%)
ICU admission 333 (63.92%)
ICU mortality 169 (50.75%)
Mechanical ventilation 263 (50.38%)
Days of MV, Median (IQR) 10 (518)
Renal replacement therapy 101 (19.31%)
Thromboembolic events 48 (9.16%)
Stroke 2 (0.38%)
Pulmonary thromboembolism 16 (3.05%)
Deep vein thrombosis 22 (4.21%)
Myocardial infarction 10 (1.92%)
ICU = intensive care unit; COPD = chronic obstructive pulmonary disease.embolism (3.05%). The median (IQR) length of hospitalization was
12 (621) days. The 28-day in-hospital mortality rate was 32.82%,
and 36.92% died during hospitalization. Figure 1 shows the survival
probability Kaplan-Meyer curve.725Medication prescriptions
Table 2 shows the prescribed medications and their length of
prescription during the first 14 days after admission. Over 80% of
the patients received ceftriaxone and azithromycin, and more than
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0% received either an optimized or anticoagulant dosage of
MWH. Few patients (<5%) received hydroxychloroquine or
vermectin. Intravenous corticosteroids were administered to
4%. A high proportion of patients (44.3%) were prescribed
euromuscular blockade and, of those, half for more than four
ays. Norepinephrine was prescribed for 43% of the patients and
pioids in nearly two-thirds of them.
Baseline comorbidities model
Table 3 shows both the univariable and final multivariable
models for baseline comorbidities and 28-day in-hospital mortali-
ty. It was found that age, chronic kidney disease, cancer, stroke,
chronic obstructive disease (COPD), and previous solid organ
transplant were associated with increased risk of mortality in the
final multivariable model. Conversely, obesity was found to be
protective. Both coronary artery disease and congestive heart
failure were no longer associated after adjustment, and sensitivity
analysis showed similar results after imputation (Supplementary
Table 3).
Admission and time-dependent models
Table 4 shows the univariable and multivariable models for
admission and follow-up (time-dependent) covariates. The uni-
variable models show hazards under-estimation at admission
compared with follow-up (time-dependent) for respiratory rate
>24/minute (1.01 versus 1.82), heart rate >100 bpm (1.19 versus
2.04), mean arterial pressure <65 mmHg (2.99 versus 3.53),
peripheral oxygen saturation <92% (1.21 versus 2.09), and all levels
of oxygen support. Risk factor differences were observed between
the admission and follow-up final multivariable models: while
only endotracheal intubation and urea levels were associated with
increased mortality risk at admission, peripheral oxygen satura-
tion <92%, intermediate oxygen support, mechanical ventilation,
CRP, neutrophil-lymphocyte ratio, urea, and LDH were associated
with increased risk of death during follow-up. Urea had more
hazards (2.25 versus 1.06) on admission compared with follow-up,
and mechanical ventilation had less hazards (1.92 versus 4.42). The
follow-up model had better performance compared with the
admission model (c-statistic 0.829 versus 0.767). None of the final
models violated Cox assumptions (global Schoenfeld residuals p >
0.05) and sensitivity analysis (Supplementary Tables 4 and 5) with
the imputed datasets showed few departures.
Figure 1. Kaplan–Meyer survival curve for 28-day in-hospital mortality.
able 2
edication prescription rates and median (IQR) number of days prescribed during the first 14 days of hospitalization.
Medication N (%) Medication N (%)
Omeprazole 376 (72%) Nitaxozamide 0 (0%)
Days, Median (IQR) 8 (513) Days, Median (IQR) 0 (00)
Ceftriaxone 433 (83%) Ivermectin 24 (5%)
Days, Median (IQR) 4 (26) Days, Median (IQR) 1 (11)
Azithromycin 445 (85%) LMWH regular 343 (65%)
Days, Median (IQR) 4 (25) Days, Median (IQR) 5 (210)
Oseltamivir 341 (65%) LMWH optimized 111 (21%)
Days, Median (IQR) 2 (14) Days, Median (IQR) 6 (2.59)
Other bacterial antibiotic 256 (49%) LMWH anticoagulant 50 (10%)
Days, Median (IQR) 6 (39) Days, Median (IQR) 6 (29)
Corticosteroids IV 233 (44%) UFH regular 208 (40%)
Days, Median (IQR) 5 (29) Days, Median (IQR) 6 (310)
Corticosteroids Oral 103 (20%) UFH optimized 33 (6%)
Days, Median (IQR) 4 (27) Days, Median (IQR) 7 (311)
Hydroxicloroquine 11 (2%) UFH anticoagulant 29 (6%)
Days, Median (IQR) 2 (16) Days, Median (IQR) 4 (26)
Fenoterol 30 (6%) NSAIDs 10 (2%)
Days, Median (IQR) 4 (16.75) Days, Median (IQR) 1 (11.75)
Ipratropium 6 (1%) Opioids 336 (64%)
Days, Median (IQR) 3 (1.254) Days, Median (IQR) 8 (412)
ACEI or ARB 124 (24%) Neuromuscular blockers 232 (44%)
Days, Median (IQR) 4 (28) Days, Median (IQR) 4 (27)
Norepinephrine 230 (44%) Erytropoietin 12 (2%)
Days, Median (IQR) 6 (39) Days, Median (IQR) 10.5 (5.512.25)
Dobutamine 34 (6%) Furosemide 279 (53%)
Days, Median (IQR) 4 (26) Days, Median (IQR) 5 (28)
MWH = low-molecular-weight heparin; UFH = un-fractioned heparin; NSAIDs = non-steroidal anti-inflammatory drugs; ACEI = angiotensin-converting enzyme inhibitor;
RB = angiotensin receptor blocker.
726
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This study described the case fatality rate and clinical correlates
of mortality among a cohort of hospitalized patients with severe
A higher rate of overall mortality was observed compared with
tertiary centers in higher-income countries (Salacup et al., 2020;
Gregoriano et al., 2020; Rieg et al., 2020; Halem et al., 2020). This
can be partly explained by the higher prevalence of severe disease
Table 3
Univariable and multivariable Cox regression models of age, sex, ethnicity, and comorbidities on 28-day in-hospital mortality.
Univariable Multivariable
Hazard ratio 95% CI Hazard ratio 95% CI
Age (every 5 years) 1.19 1.131.26 1.14 1.101.18
Sex
Female Reference Reference
Male 0.93 0.691.25 0.94 0.791.14
Ethnicity
Non-white Reference Reference
White 1.30 0.921.83 1.07 0.881.32
Past or current smoker 1 0.721.41
Comorbidities
Obesity 0.61 0.420.88 0.79 0.630.99
Hypertension 1.33 0.971.82
Diabetes 0.99 0.731.34
Congestive heart failure 1.68 1.102.57
Coronary artery disease 1.53 0.972.42
Chronic kidney disease 1.79 1.222.63 1.74 1.362.22
Cancer 2.17 1.513.12 1.84 1.452.34
Stroke 2.97 1.515.84 2.34 1.503.65
Previous transplant 1.60 0.843.04 1.90 1.322.75
COPD 2.54 1.444.48 1.79 1.262.54
Asthma 0.36 0.091.46
Auto-immune disease 1.07 0.343.36
Regular medications
ACEI or ARB 0.94 0.621.42
Concordance (C-statistic) 0.667
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker.
Table 4
Comparison of 28-day in-hospital mortality risk factors between admission and follow-up (time-dependent) models.
Admission Follow-up (time-dependent)
Univariable Multivariablea Univariable Multivariablea
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Symptom days 0.98 0.941.02 0.98 0.941.02
Vital signs
Mean arterial pressure <65 mmHg 2.99 1.535.86 1.75 0.644.77 3.53 2.255.53 1.2 0.662.17
Temperature 37.8 C 0.71 0.411.26 1.02 0.721.44
Respiratory rate >24/minute 1.01 0.751.36 1.82 1.342.46 1.18 0.801.74
Heart rate >100 bpm 1.19 0.861.65 2.04 1.502.77 1.51 0.992.31
Oxygen saturation <92% 1.21 0.881.66 1.38 0.892.16 2.09 1.552.82 1.79 1.212.63
Oxygen support
Room air Reference Reference Reference Reference
Nasal catheter 1.19 0.741.92 1.48 0.762.90 4.10 1.2213.74 1.92 0.546.87
Intermediate oxygen support 1.66 1.002.78 1.57 0.773.20 8.56 2.6028.22 2.76 0.779.91
Mechanical ventilation 1.92 1.233.00 2.02 1.083.79 12.93 4.1040.77 4.45 1.3214.97
Laboratory exams
Creatinine (mg/dL) 1.14 1.081.20 1.24 1.171.31
Urea (every 50 mg/dL) 1.64 1.471.83 2.25 1.742.91 1.54 1.401.68 1.06 1.031.08
C-reative protein (every 100 mg/dL) 1.19 1.041.35 1.47 1.311.66 1.18 1.001.40
Neutrophil/lymphocyte ratio 1.02 1.011.03 1.02 1.011.03 1.01 1.001.02
D-dimer (every 1000 ng/mL) 1.01 1.001.02 0.99 0.981.00 1.02 1.011.03
Platelets (every 100,000/mm3) 1.08 1.051.12 1.09 1.061.11 0.88 0.751.04
Lactate dehydrogenase (every 100 U/L) 0.92 0.761.12 0.76 0.670.86 1.06 1.031.09
Concordance (c-statistic) 0.767 0.829
a Adjusted for age, sex, ethinicity, comorbidities and obesity.COVID-19 in the largest tertiary publicly-funded hospital in Brazil
during the first two months of the coronavirus pandemic. In
addition, it showed that the inclusion of repeated clinical and
laboratorial measurements improved the models' predictive
performance and changed measures of association (hazard ratio)
among correlates.727and need for invasive oxygen supplementation found in this
cohort: nearly 50% of the patients needed mechanical ventilation
support compared with 12%, 19%, 22%, and 26% of patients in
similar centers in Belgium (Halem et al., 2020), Switzerland
(Gregoriano et al., 2020), United States (Salacup et al., 2020), and
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ith Germany (47%) (Rieg et al., 2020), lower than Russia (64%)
Moiseev et al., 2020) but higher than New York (22%) (Richardson
t al., 2020), Lombardy (26%) (Temel et al., 2020), and Belgium
38%) (Halem et al., 2020). This study also observed a lower rate of
enous and arterial thrombosis compared with previous literature
Al-Ani et al., 2020).
Prescription of antibiotics was very common (80%) and mostly
ncluded a combination of ceftriaxone and azithromycin in
ddition to oseltamivir. Over 45% of patients also received a
econd bacterial antibiotic during hospitalization. These rates were
igher than similar centers (Gregoriano et al., 2020; Rieg et al.,
020; Halem et al., 2020) and reflected the institutional protocol at
hat time. On the other hand, prescription of hydroxychloroquine,
vermectin and nitaxozamide was extremely low (<5%), which
ontrasts with the large proportion of patients who were
rescribed hydroxychloroquine in Switzerland (39%) (Gregoriano
t al., 2020), Germany (43%) (Rieg et al., 2020), Italy (52%)
Fumagalli et al., 2020), and the United States (60%) (Salacup et al.,
020). At that time, even though there was no evidence of a
ydroxychloroquine benefit, it is noteworthy that many institu-
ions worldwide routinely adopted its use during the initial
onths of the pandemic. The low prescription rate in the current
ohort can be explained by the lack of institutional recommenda-
ion and the skepticism regarding its use in a university-affiliated
ospital. Interestingly, although the benefit of corticosteroids in
OVID-19 was not proven at that time (Horby et al., 2020), nearly
5% of the patients received intravenous corticosteroids and of
hose, at least half for five days or more.
Consistent with previous literature (Rod et al., 2020; Wang
t al., 2020) it was found that older age, cancer, previous solid
rgan transplant, chronic renal disease, COPD, and stroke were
ssociated with increased mortality risk. No association between
revious use of ARB or ACE and mortality was observed (Zhang
t al., 2020). Commonly reported risk factors for severe disease in
eneral population studies–such as hypertension, diabetes and
ale gender–might have been underestimated because of the
election bias induced by including only tertiary hospitalized
atients. In fact, selection and collider bias can ultimately lead to
ssociation distortions (attenuation, inflation or reversal) in
bservational studies (Griffith et al., 2020) and should prompt
autious interpretation of results. Similar reasoning can be applied
o the protective effect of obesity. Although there is considerable
vidence about the association of obesity and the higher risk of
isease severity in COVID-19 patients (Palaiodimos et al., 2020;
imonnet et al., 2020; Tartof et al., 2020), once the disease
rogresses the estimated effect direction might change when only
 subset of patients is considered (obesity paradox). Similar
ndings have been observed for coronary artery disease (Gruberg
t al., 2002) and acute respiratory distress syndrome (Ni et al.,
017) and may be applicable to COVID-19; however, further studies
re needed to answer this question.
Identifying patients at higher risk of death can guide medical
ecisions and help manage hospital resources, especially in an
nder-resourced setting. Many prognosis-related factors have
een identified for COVID-19; however, most of them rely on
dmission laboratory and clinical signs (Ou et al., 2020; Wynants
t al., 2020), and consequently have limited validity for follow-up
aily reassessments. In addition, it is expected that variables
ollected at admission change their prognostic ability when
later during the course of disease. For instance, oxygen support (a
proxy for respiratory deterioration) nearly doubled the hazards
from admission because only 40% of all intubated patients were on
mechanical ventilation at admission; similar findings were
observed for heart rate, respiratory rate and mean arterial
pressure.
Similarly, laboratory tests help risk stratification but are prone
to the same bias when only admission data are included.
Consistent with prior literature (Malik et al., 2020; Rod et al.,
2020), this study showed that most studied biomarkers were
associated with mortality when unadjusted for clinical factors.
However, because it is expected that clinical tests are ordered after
clinical evaluation, it is imperative to consider their significance
according to patients' past medical history and clinical signs
(adjusted models). In this regard, this study showed that more
markers were associated with mortality during follow-up (urea,
CRP, neutrophil-lymphocyte ratio, and LDH) compared with
admission (urea), and might help physicians with patients’
prognosis during follow-up. Of those markers, the neutrophil-
lymphocyte ratio had already been shown to have prognostic
ability in a similar study with follow-up measurements (Berzuini
et al., 2020). Notably, although widely requested on admission
(>70%), no role for D-dimer was found in prognostication. Whether
it can guide future therapies, such as for anticoagulation, remains a
question and no evidence has been found for routine dosage.
Limitations are unavoidable and essential to discuss. First, this
study was from a single center and might not reflect the conditions
found in private counterparts or primary and secondary settings.
Second, the data represent the initial surge of the pandemic subject
to the learning curve. Third, chart diagnosis was considered for
comorbidities and therefore prone to under-reporting or mea-
surement error (obesity). Fourth, because of test unavailability,
there were no data on IL-6 levels, which may have had a role in the
prognosis of COVID-19 infected patients. Finally, treatments were
heterogeneous and medication prescriptions and outcomes were
not addressed.
Strengths of this study included the detailed description of
different outcomes and medication prescription rates among
hospitalized patients from a tertiary public hospital in Brazil, and
the analysis of follow-up measurements and their clinical
interpretation for COVID-19 prognosis, which few previous studies
have taken into consideration (Berzuini et al., 2020).
In summary, this study described the clinical outcomes and
patterns of prescription during the first two months of the COVID-
19 pandemic in a tertiary center in Brazil. The incorporation of
follow-up measurements, in addition to improving mortality
prediction, changed the mortality hazards of vital signs and
biomarkers compared with admission. Peripheral oxygen satura-
tion, oxygen support, LDH, urea, C-reactive protein, and neutro-
phil-lymphocyte ratio, in addition to previously known
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epeated measurements are included. As an example, this study
howed that clinical signs hazards were under-estimated at
dmission compared with follow-up; this possibly happened
ecause vital signs capture late changes that are ultimately
ssociated with death (Bruera et al., 2014) and are under-
epresented at admission for most patients who will die much72Availability of data and material
Data are available from the authors upon reasonable request.8
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